A non‐human primate model for the study of oral iron chelators
- 1 July 1989
- journal article
- research article
- Published by Wiley in British Journal of Haematology
- Vol. 72 (3) , 456-461
- https://doi.org/10.1111/j.1365-2141.1989.tb07732.x
Abstract
Summary. Recent studies have demonstrated that parenteral deferroxamine can prolong life in patients with iron overload. We have developed a non‐human primate model of iron overload and have accurately determined negative iron balance in parenteral and oral studies of deferroxamine and a new chelator, desferrithiocin. Cebus monkeys were loaded with iron dextran (10 mg/kg twice weekly) until their serum contained a transferrin saturation >75%, and (in two animals) liver biopsies showed iron loading. When complete iron balance studies were performed at this time, basal iron balance was −53 ± 11 μg (N=4), providing a low back ground for provocative studies. Iron balance was determined for intramuscular (N= 2) and oral (N=3) deferroxamine, as well as intramuscular (N= 1) and oral (N= 4) desferrithiocin. The pattern of iron excretion after parenteral deferroxamine strongly resembled that of the iron‐loaded, transfused human. Desferrithiocin was found to have significant activity as an oral chelator. This Cebus monkey model accurately determines negative iron balance and readily permits precise comparison of iron chelators given parenterally or orally. This model may offer an important step between rodent and human trials of promising new iron chelators.This publication has 17 references indexed in Scilit:
- 1,2-DIMETHYL-3-HYDROXYPYRID-4-ONE, AN ORALLY ACTIVE CHELATOR FOR TREATMENT OF IRON OVERLOADThe Lancet, 1987
- Orally active α-ketohydroxy pyridine iron chelators intended for clinical use: in vivo studies in rabbitsBritish Journal of Haematology, 1986
- Prevention of Cardiac Disease by Subcutaneous Deferoxamine in Patients with Thalassemia MajorNew England Journal of Medicine, 1985
- DESFERRIOXAMINE TO IMPROVE CARDIAC FUNCTION IN IRON-OVERLOADED PATIENTS WITH THALASSAEMIA MAJORThe Lancet, 1984
- Survival and desferrioxamine in thalassaemia major.BMJ, 1982
- THE STATUS OF NEW IRON CHELATORS*Annals of the New York Academy of Sciences, 1980
- Non‐Specific Serum Iron in Thalassaemia: an Abnormal Serum Iron Fraction of Potential ToxicityBritish Journal of Haematology, 1978
- Long-term Chelation Therapy in Thalassaemia Major: Effect on Liver Iron Concentration, Liver Histology, and Clinical ProgressBMJ, 1974
- Storage Iron KineticsBritish Journal of Haematology, 1973
- SYNTHETIC CHELATING AGENTS IN IRON METABOLISM*Journal of Clinical Investigation, 1963